Open Beta
TREN
MetriLume
TREN

US marketsINO

SEC-sourced researchBeta

INO

INOVIO PHARMACEUTICALS, INC.

Company comparison ↗

Data passport

CIK
0001055726
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 6, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 217,756.0000 USD; December 2025: 65,343.0000 USD217.8K USD0 USD0December 2024December 2025
INO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024217,756.0000Mar 12, 2026
December 202565,343.0000Mar 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202565,343.0000-84,945,901.0000-88,629,430.000074,310,035.000050,213,759.0000Mar 12, 2026
December 2024217,756.0000-107,254,126.0000-104,076,553.0000113,197,206.000044,693,411.0000Mar 12, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$65.34KDecember 2025Mar 12, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$217.76KDecember 2024Mar 12, 202610-K
Net incomeNetIncomeLoss-$84.95MDecember 2025Mar 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$88.63MDecember 2025Mar 12, 202610-K
Total assetsAssets$74.31MDecember 2025Mar 12, 202610-K
Total liabilitiesLiabilities$50.21MDecember 2025Mar 12, 202610-K

New filings

Explore methodology ↗